Insulin detemir: A historical perspective on a modern basal insulin analogue

Luigi Meneghini; Andreas Liebl; Martin J. Abrahamson

doi:10.1016/S1751-9918(10)60007-1

Insulin detemir: A historical perspective on a modern basal insulin analogue

Luigi Meneghini, Andreas Liebl, Martin J. Abrahamson

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets.

Original language	English (US)
Pages (from-to)	S31-S42
Journal	Primary care diabetes
Volume	4
DOIs	https://doi.org/10.1016/S1751-9918(10)60007-1
State	Published - Apr 2010

Keywords

Basal insulin analogue
Hypoglycemia
Insulin detemir
Weight gain

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Nutrition and Dietetics

Access to Document

10.1016/S1751-9918(10)60007-1

Cite this

@article{828b23e5eb93407e8b12c428d466fd15,

title = "Insulin detemir: A historical perspective on a modern basal insulin analogue",

abstract = "Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets.",

keywords = "Basal insulin analogue, Hypoglycemia, Insulin detemir, Weight gain",

author = "Luigi Meneghini and Andreas Liebl and Abrahamson, {Martin J.}",

note = "Funding Information: All authors have been involved throughout the development of the manuscript, from initial concept to providing final approval. The meeting upon which this manuscript is based was funded by Novo Nordisk. Novo Nordisk was involved in the selection of faculty for this meeting, who were paid an honorarium for speaking. The authors thank Murray Edmunds, Watermeadow Medical, UK, for writing assistance in the development of this manuscript; this assistance was funded by Novo Nordisk, who also had a role in review of the manuscripts for scientific accuracy. Publisher Copyright: {\textcopyright} 2010 Primary Care Diabetes Europe",

year = "2010",

month = apr,

doi = "10.1016/S1751-9918(10)60007-1",

language = "English (US)",

volume = "4",

pages = "S31--S42",

journal = "Primary care diabetes",

issn = "1751-9918",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Insulin detemir

T2 - A historical perspective on a modern basal insulin analogue

AU - Meneghini, Luigi

AU - Liebl, Andreas

AU - Abrahamson, Martin J.

N1 - Funding Information: All authors have been involved throughout the development of the manuscript, from initial concept to providing final approval. The meeting upon which this manuscript is based was funded by Novo Nordisk. Novo Nordisk was involved in the selection of faculty for this meeting, who were paid an honorarium for speaking. The authors thank Murray Edmunds, Watermeadow Medical, UK, for writing assistance in the development of this manuscript; this assistance was funded by Novo Nordisk, who also had a role in review of the manuscripts for scientific accuracy. Publisher Copyright: © 2010 Primary Care Diabetes Europe

PY - 2010/4

Y1 - 2010/4

N2 - Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets.

AB - Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets.

KW - Basal insulin analogue

KW - Hypoglycemia

KW - Insulin detemir

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=77954930050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954930050&partnerID=8YFLogxK

U2 - 10.1016/S1751-9918(10)60007-1

DO - 10.1016/S1751-9918(10)60007-1

M3 - Article

C2 - 20394890

AN - SCOPUS:77954930050

SN - 1751-9918

VL - 4

SP - S31-S42

JO - Primary care diabetes

JF - Primary care diabetes

ER -

Insulin detemir: A historical perspective on a modern basal insulin analogue

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this